Skip to main content
TipRanks
Go Ultimate75% OFF

M K Proteins Limited (MKPL) AI Stock Analysis

0 Followers
IN:MKPL

M K Proteins Limited

(NSE:MKPL)

Select Model
Rating:47Neutral
Price Target:INR 4.00â–¼(-0.25% Downside)
Action:reiterated
Date:09/06/26

The score is held back primarily by weak cash-flow conversion and deteriorating margins despite strong FY2026 revenue growth. Technicals are also bearish (price below key moving averages and negative MACD), while valuation appears high (P/E ~32) with no dividend yield provided.

Positive Factors
Revenue ReboundThe strong FY2026 sales rebound shows the business can regain demand after weaker years. Sustained revenue growth would improve operating leverage and provide a larger base from which to rebuild profitability.
Negative Factors
Severe Margin CompressionThe sharp decline in gross and net margins signals weaker pricing power, higher costs, or an unfavorable mix. Unless margins stabilize, additional revenue may translate into limited earnings and weaker resilience.

M K Proteins Limited (MKPL) vs. iShares MSCI India ETF (INDA)

-50%-40%-30%-20%-10%0%10%IN:MKPL-38.40%INDA-5.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 1.51B
Dividend Yield
―
Average Volume (3M)
21.13K
Price to Earnings (P/E)
32.0
Beta (1Y)
0.87
Revenue Growth
17.76%
EPS Growth
-50.16%
Country
India
Employees
54
Sector
General
Sector Strength
55
Industry
Packaged Foods

M K Proteins Limited Business Overview & Revenue Model

Company Description

M. K. Proteins Limited specializes in the production and commercial activities related to a range of refined vegetable oils and their associated derivatives. The company's diverse offerings include refined varieties such as rice bran, sunflower, cott...

M K Proteins Limited Financial Statement Overview

Summary

Overall financial quality is mixed: revenue rebounded strongly in FY2026 (+17.7% YoY), and leverage improved (debt-to-equity ~0.49). However, profitability compressed sharply (gross margin ~2.9% and net margin ~1.8% in FY2026), and cash generation is weak/volatile with multiple years of negative operating cash flow and modest FY2026 free cash flow versus earnings.

Income Statement

55Neutral

Balance Sheet

72Positive

Cash Flow

34Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue3.83B3.83B2.68B2.46B3.15B2.56B
Gross Profit107.65M144.45M156.53M192.91M180.64M186.78M
EBITDA85.46M116.77M129.08M170.99M176.52M157.88M
Net Income46.98M68.29M83.97M112.12M109.35M101.84M
Balance Sheet
Total Assets01.31B1.31B962.46M1.03B861.48M
Cash, Cash Equivalents and Short-Term Investments4.38M4.38M338.00K923.24K624.84K66.62K
Total Debt0371.38M387.24M200.83M455.35M367.84M
Total Liabilities-763.00M548.97M611.04M351.70M533.55M465.44M
Stockholders Equity763.00M763.00M694.66M610.76M498.64M396.04M
Cash Flow
Free Cash Flow019.10M-183.51M265.13M-58.80M-116.95M
Operating Cash Flow038.05M-161.28M324.16M-58.73M-101.22M
Investing Cash Flow0-17.18M-14.82M-58.78M133.85K-15.28M
Financing Cash Flow0-16.83M175.52M-265.08M59.15M116.56M

M K Proteins Limited Technical Analysis

Technical Analysis SentimentPositive
Last Price4.01

Price Trends

50DMA3.96Positive
100DMA4.19Negative
200DMA4.64Negative

Market Momentum

MACD-0.01Negative
RSI55.49Neutral
STOCH73.05Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MKPL, the sentiment is Positive. The current price of 4.01 is above the 20-day moving average (MA) of 3.87, above the 50-day MA of 3.96, and below the 200-day MA of 4.64, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 55.49 is Neutral, neither overbought nor oversold. The STOCH value of 73.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:MKPL.

M K Proteins Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:MKPL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:GOKULAGROIN:GOKULAGRO81OutperformINR 66.87B14.46――14.83%58.34%
IN:MUKKAIN:MUKKA67NeutralINR 8.31B10.29――84.77%67.73%
IN:KRITINUTIN:KRITINUT62NeutralINR 3.24B10.86―0.46%17.56%-4.84%
IN:ROMLIN:ROML56NeutralINR 667.53M15.07――15.31%-22.36%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:MKPLIN:MKPL47NeutralINR 1.49B32.02――17.76%-50.16%
IN:GOKULIN:GOKUL42NeutralINR 3.56B17.94――15.39%27.60%

* General Sector Average

Performance Comparison

-40%-20%0%20%IN:MKPLIN:GOKULIN:GOKULAGROIN:KRITINUTIN:MUKKAIN:ROMLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:MKPL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:MKPLM K Proteins Limited4.01-2.68-40.06%
IN:GOKULGokul Refoils & Solvent Ltd.37.41-2.69-6.71%
IN:GOKULAGROGokul Agro Resources Ltd.227.5031.1015.84%
IN:KRITINUTKriti Nutrients Limited64.92-22.61-25.83%
IN:MUKKAMukka Proteins Limited27.280.913.45%
IN:ROMLRaj Oil Mills Limited42.30-8.20-16.24%

M K Proteins Limited Corporate Events

M K Proteins Closes Trading Window Ahead of Q1 FY2026 Results

Jun 27, 2026

M K Proteins Limited has announced the closure of its trading window for company shares starting 1 July 2026, in line with SEBI’s Prohibition of Insider Trading Regulations and its own code of conduct, covering employees, directors, key managerial pe...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 06, 2026